Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants

Amplified FGFR2 has been shown to be a potential target for a number of ATP-competitive inhibitors, some of which are currently in clinical trials for therapeutic use (Takeda, 2007; Turner, 2010; http://clinicaltrials.gov).

增强型FGFR2已被证实为多种ATP竞争性抑制剂的目标，其中一些抑制剂目前正处于临床试验阶段，用于治疗目的（Takeda, 2007；Turner, 2010；http://clinicaltrials.gov）。